General Information of Drug (ID: DMFBNA3)

Drug Name
Nicaraven Drug Info
Synonyms AVS; Antevan; Antevas
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular disease 8B2Z Phase 3 [1]
Cross-matching ID
PubChem CID
71234
CAS Number
CAS 79455-30-4
TTD Drug ID
DMFBNA3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicotinamide DMUPE07 Acne vulgaris ED80 Approved [2]
KU-0058948 DMSA4HZ Ovarian cancer 2C73 Approved [3]
Niraparib Tosylate DMLPSWQ Fallopian tube cancer 2C74 Approved [4]
CC-486 DMTNQB0 Acute myeloid leukaemia 2A60 Phase 3 [5]
PMID27841036-Compound-37 DM0OVZ2 Ovarian cancer 2C73 Phase 2 [6]
Stenoparib DMKVBL8 Ovarian cancer 2C73 Phase 2 [7]
AG140699 DMA9FKY Melanoma 2C30 Phase 2 [8]
AZD5305 DMW9R1C Prostate cancer 2C82.0 Phase 2 [9]
AMXI 5001 DMR9H6B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
NMS-03305293 DM2XIRW Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase 1 (PARP1) TTVDSZ0 PARP1_HUMAN Modulator [1]

References

1 Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
2 beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
3 Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
6 PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
7 Clinical pipeline report, company report or official report of Allarity Therapeutics.
8 Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
9 Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
10 AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
11 NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.